Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Lu AF28996 in Healthy Young Men
NCT03565094Phase 1Completed
- Sponsor
- Lundbeck
- Start
- May 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Lu AF28996 in Parkinson's disease (PD), sponsored by Lundbeck. Primary endpoints: Area Under the Curve From Time Zero to Infinity at Day 12, Maximum Plasma Concentration at Day 12 and 1 more. Started May 2018; status: completed.
02
Drugs
Lu AF28996
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03565094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03565094.